Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R107
- Development stage
- Phase 2
- Lead developer
- Tasman Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
R107 is an investigational, oral, extended-release formulation of racemic ketamine. Developed by Douglas Pharmaceuticals in collaboration with Zenith Technology, it is intended for the treatment of treatment-resistant depression (TRD) and various anxiety disorders, such as social anxiety disorder (SAD) and generalized anxiety disorder (GAD). As an NMDA receptor antagonist, ketamine works by modulating glutamatergic neurotransmission. The R107 formulation is specifically designed to release the active ingredient slowly, aiming to reduce the peak plasma concentrations that cause dissociative and cardiovascular side effects, thereby allowing for potential at-home administration. In the Phase 2 BEDROC trial, R107 demonstrated a statistically significant reduction in depression scores compared to placebo.
- Other names
- racemic ketamine extended-release tablet
02
Targets
DAT (Dopamine plasma membrane transport protein)NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on R107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R107.